NASDAQ · Biotechnology

Bicycle Therapeutics plc (BCYC) Stock

$4.22 +0.24% NASDAQ: BCYC Healthcare

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments.

Valuation

MetricValue
Price$4.22
Market Cap$292.84M
P/E Ratio-1.34
P/B Ratio0.53
P/S Ratio4.61
EPS (TTM)$-3.16
52-Week High$9.18
52-Week Low$3.92
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.74%
ROA-33.57%
ROCE-40.17%
Gross Margin-11.86%
Operating Margin-381.75%
Net Margin-344.95%
Debt/Equity0.03
Current Ratio12.66

Annual Financials (USD)

Metric20212022202320242025
Revenue$12.0M$14.0M$27.0M$35.0M$73.0M
Operating Profit$-66.0M$-117.0M$-190.0M$-210.0M$-248.0M
Net Profit$-67.0M$-113.0M$-181.0M$-169.0M$-219.0M
EPS$-2.67$-3.80$-5.08$-2.90$-3.16
Op Margin-561.0%-806.6%-704.1%-595.0%-341.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$480.0M$411.0M$595.0M$957.0M$718.0M
Total Liabilities$134.0M$140.0M$224.0M$164.0M$108.0M
Cash$439.0M$339.0M$526.0M$880.0M$628.0M
Borrowings$44.0M$44.0M$45.0M$9.0M$18.0M

Latest News

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? Zacks · Jul 3, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading MT Newswires · Jun 30, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading MT Newswires · Jun 17, 2026 European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading MT Newswires · Jun 16, 2026 European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading MT Newswires · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-86.0M$-61.0M$-165.0M$-250.0M
Investing Cash Flow$-4.0M$-38.0M$-6.0M$-2.0M$-5.0M
Financing Cash Flow$7.0M$1.0M$1.0M$8.0M$0
Net Cash Flow$303.0M$-100.0M$188.0M$353.0M$-251.0M
Free Cash Flow$-17.0M$-105.0M$-64.0M$-166.0M$-253.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.37
EV / EBITDA1.19
FCF Yield-78.20%
Quick Ratio12.66
Interest Coverage-1194.08
Return 1Y-52.24%
Return 3Y-83.89%
Return 5Y-87.59%

Ownership

Insiders Held4.49%
Institutions Held73.77%
Institutions Float Held77.23%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP10,885,3572026-03-31
FCPM III Services B.V.3,468,4302026-03-31
Armistice Capital, LLC3,398,0002026-03-31
Long Focus Capital Management, LLC3,310,6872026-03-31
Acadian Asset Management. LLC1,968,0252026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics S.A. $1.19 +3.48% -1.09 $151.36M 0.00%
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
FULC $3.73 +0.13% -5.17 $201.56M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

Bicycle Therapeutics plc is headquartered in GB.

Bicycle Therapeutics plc (BCYC) stock trades at $4.22 with a market capitalization of $292.84M. The stock is valued at a price-to-earnings (P/E) ratio of -1.34, price-to-book of 0.53, price-to-sales of 4.61. Over the past 52 weeks the stock has ranged between $3.92 and $9.18, and currently trades 54.0% below its 52-week high.

On profitability, Bicycle Therapeutics plc generates a return on equity (ROE) of -35.74%, return on capital employed of -40.17%, an operating margin of -381.75%, a net profit margin of -344.95%.

Official website: www.bicycletherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides